These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26458194)

  • 1. Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis: Is Intrathecal Anti-CD20 a Therapeutic Option?
    Fereidan-Esfahani M; Brück W; Weber MS
    JAMA Neurol; 2015 Dec; 72(12):1407-8. PubMed ID: 26458194
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
    Studer V; Rossi S; Motta C; Buttari F; Centonze D
    J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD21 positive B cell: a novel target for treatment of multiple sclerosis.
    Farjam M; Ebrahimpour A; Fakhraei B
    Med Hypotheses; 2013 May; 80(5):556-7. PubMed ID: 23384704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.
    Li R; Bar-Or A
    Cold Spring Harb Perspect Med; 2019 Apr; 9(4):. PubMed ID: 29661809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
    Zanotti C; Chiarini M; Serana F; Sottini A; Garrafa E; Torri F; Caimi L; Rasia S; Capra R; Imberti L
    Clin Immunol; 2012 Oct; 145(1):19-26. PubMed ID: 22892399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix.
    Vugmeyster Y; Howell K; Bakshl A; Flores C; Canova-Davis E
    Cytometry A; 2003 Apr; 52(2):101-9. PubMed ID: 12655653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab and multiple sclerosis.
    Kitsos DK; Tsiodras S; Stamboulis E; Voumvourakis KI
    Clin Neuropharmacol; 2012; 35(2):90-6. PubMed ID: 22421587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis.
    Okuda Y; Sakoda S; Fujimura H; Nagata S; Yanagihara T; Bernard CC
    Biochem Biophys Res Commun; 2000 Aug; 275(1):164-8. PubMed ID: 10944459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on multiple sclerosis.
    Hauser SL
    J Neurol Sci; 2005 Feb; 228(2):193-4. PubMed ID: 15694203
    [No Abstract]   [Full Text] [Related]  

  • 10. B cells: no longer the nondominant arm of multiple sclerosis.
    Klawiter EC; Cross AH
    Curr Neurol Neurosci Rep; 2007 May; 7(3):231-8. PubMed ID: 17488589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys.
    Vugmeyster Y; Howell K; McKeever K; Combs D; Canova-Davis E
    Int Immunopharmacol; 2003 Oct; 3(10-11):1477-81. PubMed ID: 12946444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists.
    Kulik L; Chen K; Huber BT; Holers VM
    Mol Immunol; 2011 Mar; 48(6-7):883-94. PubMed ID: 21269698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 14. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA; Sánchez AJ
    Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedside to bench: betting on B cells in multiple sclerosis.
    Link H
    Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578
    [No Abstract]   [Full Text] [Related]  

  • 16. The B lymphocyte as an immunotherapeutic target.
    Fearon DT
    QJM; 1995 Mar; 88(3):149-53. PubMed ID: 7539331
    [No Abstract]   [Full Text] [Related]  

  • 17. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 18. Intrathecal immune reset in multiple sclerosis: exploring a new concept.
    Bonnan M
    Med Hypotheses; 2014 Mar; 82(3):300-9. PubMed ID: 24417802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
    Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
    Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New concepts in the immunopathogenesis of multiple sclerosis.
    Hemmer B; Archelos JJ; Hartung HP
    Nat Rev Neurosci; 2002 Apr; 3(4):291-301. PubMed ID: 11967559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.